Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cutaneous Lupus Erythematosus (CLE): early-phase trial registry
3 of 3 indexed Cutaneous Lupus Erythematosus (CLE) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 3 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Cutaneous Lupus Erythematosus (CLE): 3 US clinical trials tracked, 3 recruiting.
Cutaneous Lupus Erythematosus (CLE) is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Ventus Therapeutics U.S., running 1 of these trials.
Enrollment posture brief
Registry condition cutaneous-lupus-erythematosus-cle
OPEN 3 | RECR 100% | LATE 0 | EARLY 1 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Cutaneous Lupus Erythematosus (CLE) lists 3 open slots (100% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cutaneous Lupus Erythematosus (CLE) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cutaneous Lupus Erythematosus (CLE) is recruiting above its size-band peers.
3 of 3 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Research Accelerated by You Lupus Registry
Lupus Foundation of America
NCT06927219
Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus
University of Pennsylvania
NCT01510067
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
Ventus Therapeutics U.S.
NCT07260877
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Cutaneous Lupus Erythematosus (CLE) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cutaneous Lupus Erythematosus (CLE) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cutaneous Lupus Erythematosus (CLE) page
3 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Cutaneous Lupus Erythematosus (CLE) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Ventus Therapeutics U.S. sponsors the most Cutaneous Lupus Erythematosus (CLE) trials on record, review their full trial history before evaluating a specific study. See Ventus Therapeutics U.S.'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cutaneous Lupus Erythematosus (CLE) condition card totals 3 registered trials; most-linked intervention VENT-03; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.